Can doubling the dose stop prostate cancer from worsening?
NCT ID NCT03458247
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at men with advanced prostate cancer that no longer responds to hormone therapy. When the standard dose of abiraterone stopped working, some patients received a double dose to see if it could stabilize the disease. The goal was to find out if this approach is safe and effective for those with low drug levels in their blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- abiraterone acetate
- What this could lead to
- If successful, this could show that a higher dose of abiraterone helps control prostate cancer longer in patients who start to progress on the standard dose.
- What could go wrong
- This is a small, early-phase study without a comparison group, so results may not be definitive. Higher doses may also increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Medical Oncology, Cochin Hospital
Paris, Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new pill outsmart resistant prostate cancer?
- A second look: MRI screening may spot hidden prostate cancers
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?